| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
167,290,000 |
| Market
Cap: |
182.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6061 - $2.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile X4 Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary product candidate is mavorixafor, a small molecule chemokine receptor type 4 (CXCR4) antagonist that inhibits receptor binding by CXCL12, the cognate ligand of CXCR4. Co. is conducting clinical trials of mavorixafor: for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene; and in people with chronic neutropenia and Waldenstrom's macroglobulinemia, a rare B-cell lymphoproliferative disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
25,000 |
25,000 |
| Total Buy Value |
$0 |
$0 |
$29,875 |
$29,875 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
185,708 |
185,708 |
353,799 |
624,831 |
| Total Sell Value |
$170,713 |
$170,713 |
$383,960 |
$557,665 |
| Total People Sold |
4 |
4 |
5 |
6 |
| Total Sell Transactions |
8 |
8 |
19 |
42 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cadavid Diego |
Chief Medical Officer |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
8,035 |
8,035 |
|
- |
|
| Ragan Paula |
President and CEO |
• • – |
2021-03-02 |
4 |
AS |
$9.74 |
$23,376 |
D/D |
(2,400) |
272,923 |
|
-34% |
|
| Ragan Paula |
President and CEO |
• • – |
2021-02-02 |
4 |
AS |
$7.88 |
$18,912 |
D/D |
(2,400) |
275,323 |
|
6% |
|
| Ragan Paula |
President and CEO |
• • – |
2021-01-05 |
4 |
AS |
$7.00 |
$16,800 |
D/D |
(2,400) |
277,723 |
|
11% |
|
| Ragan Paula |
President and CEO |
• • – |
2020-12-23 |
4 |
AS |
$7.00 |
$33,600 |
D/D |
(4,800) |
280,123 |
|
14% |
|
| Lawton Alison Francis |
Director |
– • – |
2020-10-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,134 |
|
20% |
|
| Ragan Paula |
President and CEO |
• • – |
2020-10-05 |
4 |
AS |
$7.00 |
$12,579 |
D/D |
(1,797) |
284,923 |
|
20% |
|
| Ragan Paula |
President and CEO |
• • – |
2020-10-02 |
4 |
AS |
$7.00 |
$4,221 |
D/D |
(603) |
286,720 |
|
33% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2020-09-21 |
4 |
AS |
$7.08 |
$76,705 |
D/D |
(10,834) |
29,589 |
|
12% |
|
| Skerlj Renato |
Chief Scientific Officer |
• – – |
2020-09-09 |
4 |
AS |
$8.05 |
$46,964 |
D/D |
(5,834) |
42,076 |
|
-7% |
|
| Ragan Paula |
President and CEO |
• • – |
2020-09-09 |
4 |
AS |
$8.04 |
$71,074 |
D/D |
(8,840) |
287,323 |
|
-7% |
|
| Meisner Derek M |
General Counsel |
• – – |
2020-09-09 |
4 |
AS |
$8.05 |
$67,089 |
D/D |
(8,334) |
16,666 |
|
-7% |
|
| Ragan Paula |
President and CEO |
• • – |
2020-09-02 |
4 |
AS |
$7.99 |
$19,176 |
D/D |
(2,400) |
296,163 |
|
1% |
|
| Skerlj Renato |
Chief Scientific Officer |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
47,910 |
|
- |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
40,423 |
|
- |
|
| Ragan Paula |
President and CEO |
• • – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
44,825 |
298,563 |
|
- |
|
| Meisner Derek M |
General Counsel |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
25,000 |
|
- |
|
| Skerlj Renato |
Chief Scientific Officer |
• – – |
2020-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
39,160 |
|
- |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2020-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
24,173 |
|
- |
|
| Ragan Paula |
President and CEO |
• • – |
2020-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
44,826 |
253,738 |
|
- |
|
| Meisner Derek M |
General Counsel |
• – – |
2020-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
12,500 |
|
- |
|
| Ragan Paula |
President and CEO |
• – – |
2020-08-03 |
4 |
AS |
$7.45 |
$17,880 |
D/D |
(2,400) |
208,912 |
|
-23% |
|
| Ragan Paula |
President and CEO |
• – – |
2020-07-02 |
4 |
AS |
$9.05 |
$21,720 |
D/D |
(2,400) |
211,312 |
|
-26% |
|
| Mostafa Adam S. |
See Remarks |
• – – |
2020-06-30 |
4 |
D |
$9.32 |
$8,537 |
D/D |
(916) |
7,923 |
|
- |
|
| Mostafa Adam S. |
See Remarks |
• – – |
2020-06-30 |
4 |
AS |
$9.04 |
$15,594 |
D/D |
(1,725) |
8,839 |
|
-31% |
|
160 Records found
|
|
Page 5 of 7 |
|
|
0.11 (9.17%) 
